Abivax SA American Depositary Shares (ABVX)

Price$129.69

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-5.40%

Price vs S&P 500 (4W)8.31%

VGM Score69.49

Market Capitalization$10.54B

All Metrics

Book Value / Share (Quarterly)$6.75

P/TBV (Annual)20.15x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.32

Price vs S&P 500 (YTD)-15.93%

EPS (TTM)$-6.19

10-Day Avg Trading Volume0.59M

EPS Excl Extra (TTM)$-6.19

EPS (Annual)$-5.63

ROI (Annual)-73.54%

Gross Margin (Annual)-19700.00%

Cash / Share (Quarterly)$7.98

ROA (Last FY)-57.52%

EBITD / Share (TTM)$-4.83

ROE (5Y Avg)-314.42%

Cash Flow / Share (Annual)$-2.32

P/B Ratio19.87x

P/B Ratio (Quarterly)19.86x

Net Income / Employee (Annual)$-5,759,843

Net Interest Coverage (TTM)-5.62x

ROA (TTM)-133.81%

EPS Incl Extra (Annual)$-5.63

Current Ratio (Annual)8.75x

Quick Ratio (Quarterly)8.71x

3-Month Avg Trading Volume0.21M

52-Week Price Return1497.18%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$6.66

P/S Ratio (Annual)904533.00x

Asset Turnover (Annual)0.00x

52-Week High$132.00

EPS Excl Extra (Annual)$-5.63

CapEx CAGR (5Y)-30.85%

Tangible BV CAGR (5Y)142.88%

26-Week Price Return10.53%

Quick Ratio (Annual)8.71x

13-Week Price Return6.98%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.75x

Enterprise Value$9.94B

Book Value / Share Growth (5Y)77.81%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-58600.00%

Cash / Share (Annual)$7.98

3-Month Return Std Dev55.77%

Net Income / Employee (TTM)$-6,590,369

ROE (Last FY)-73.84%

Net Interest Coverage (Annual)-5.89x

EPS Basic Excl Extra (Annual)$-5.63

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-6.19

Receivables Turnover (Annual)0.00x

ROI (TTM)-51.49%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.66

Price vs S&P 500 (52W)1468.98%

Year-to-Date Return-5.81%

5-Day Price Return-1.48%

EPS Normalized (Annual)$-5.63

ROA (5Y Avg)-61.29%

Net Profit Margin (Annual)-50800.00%

Month-to-Date Return17.57%

Cash Flow / Share (TTM)$-3.49

EBITD / Share (Annual)$-4.11

Operating Margin (Annual)-57900.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-86.76%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-6.19

P/TBV (Quarterly)20.15x

P/B Ratio (Annual)19.86x

Book Value / Share (Annual)$6.75

Price vs S&P 500 (13W)-2.77%

Beta0.46x

Revenue / Share (TTM)$0.00

ROE (TTM)-51.69%

52-Week Low$5.12

mGradeB

vgmGradeB

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.29

About

Abivax is a French clinical-stage biotechnology company developing therapeutics designed to regulate immune response in chronic inflammatory diseases. The company's lead candidate, obefazimod, is in Phase 3 development for moderately to severely active ulcerative colitis. Abivax focuses on inflammatory bowel disease, including both ulcerative colitis and Crohn's disease.